Variant Bio

Right on the heels of our press release announcing a deal with Novo Nordisk, we're thrilled to see this NY Times coverage of the partnership and Variant Bio's ethics-first approach to drug discovery: nytimes.com/2025/01/07/hea…

“They’re solving the biggest bottleneck that exists in drug discovery.” -- John Xue, SoftBank Investment Advisers (for more, read the recent Sōzō Insights feature piece highlighting Variant Bio's unique approach to drug discovery): visionfund.com/insights/varia…

Explore our life sciences thesis by Alessandra, Ken, and Elena ↓ generalcatalyst.com/stories/the-fu…

Since 2021, we’ve invested approximately $700M across more than 30 companies, partnering at every stage—from seed and company creation to public market entry—to seek to drive innovation in this space. Breakthroughs in biology are converging with advances in applied AI and…

Our SABR manuscript is out in Nature Genetics. SABR is the largest functional genomics dataset from a continental African cohort. We mapped the genetic architecture of blood expression, splicing, and cell types in over 600 individuals from 3 SEB groups. nature.com/articles/s4158…

Variant Bio and @WitsUniversity unveil the largest functional genomics resource ever created for a continental African population out now in @NatureGenet: medium.com/variantbio/ann…

Team members from @VariantBio visited Brisbane, Australia to present on genomics research and meet with study collaborators in Queensland: medium.com/variantbio/a-t…

Variant Bio visits long-term partners in the Faroe Islands to celebrate the end of participant recruitment and kick off data generation together: medium.com/variantbio/cel…

We have distributed over $1 million USD in short-term benefits for genomic research projects spanning six continents: medium.com/variantbio/var…

Such a thought-provoking and important discussion with co-panelists Drs. June Fabian, Keolu Fox, and Valerie Luyckx, now available to view here: live.publicpolicyprojects.com/GlobalGenomics…

We are proud to be among the sponsors of the 15th African Society for Human Genetics conference taking place in Uganda this week, and to see Olivia Gray from Variant Bio and @StephieBioanth from University of Antananarivo both presenting about our project together in Madagascar.

Variant Bio aims to study immune function across diverse populations with new funding from the Bill & Melinda Gates Foundation: medium.com/variantbio/var…

There are a number of genomics startups that have sprouted up to strengthen their sequencing technologies to aid in disease prevention and treatment.  labiotech.eu/best-biotech/g…

Asst Prof @TrinidadSu56273 discusses ethics research with @KUOW's @RadioGirlMurphy after @VariantBio announces plans for benefit-sharing with indigenous communities for their genetic contributions to drug dev research! Listen here: kuow.org/stories/seattl…

Listen to Seattle's NPR coverage of Variant Bio's new partnership with Novo Nordisk and our approach to making human genomic research and drug discovery both more ethical and equitable: kuow.org/stories/seattl…

A television segment about Variant Bio's partnership with Novo Nordisk and our approach to genomic research on TVNZ 1News, New Zealand's national broadcaster: 1news.co.nz/2025/01/16/new…

Hot off the printed press this morning — Variant Bio’s partnership with Novo Nordisk featured on the front page of the @nytimes:

More coverage of Variant Bio's exciting new partnership with Novo Nordisk in today's print edition of the @seattletimes:

Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m. pharmaceutical-technology.com/news/variant-n…